These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 18537180

  • 1. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound.
    Warner N, Locarnini S.
    Hepatology; 2008 Jul; 48(1):88-98. PubMed ID: 18537180
    [Abstract] [Full Text] [Related]

  • 2. The impact of the hepatitis B virus polymerase rtA181T mutation on replication and drug resistance is potentially affected by overlapping changes in surface gene.
    Ahn SH, Park YK, Park ES, Kim JH, Kim DH, Lim KH, Jang MS, Choe WH, Ko SY, Sung IK, Kwon SY, Kim KH.
    J Virol; 2014 Jun; 88(12):6805-18. PubMed ID: 24696492
    [Abstract] [Full Text] [Related]

  • 3. Hepatitis B e antigen-suppressing mutations enhance the replication efficiency of adefovir-resistant hepatitis B virus strains.
    Herbers U, Amini-Bavil-Olyaee S, Mueller A, Luedde T, Trautwein C, Tacke F.
    J Viral Hepat; 2013 Feb; 20(2):141-8. PubMed ID: 23301549
    [Abstract] [Full Text] [Related]

  • 4. Hepatitis B virus rtA181T/sW172non-stop mutation may increase resistance fold to adefovir- and entecavir-resistant mutants compared to rtA181T/sW172* mutation.
    Zhao L, Li X, Cheng Y, Chen R, Shao J, Zhou Y, Li Q, Liao H, Zhao Y, Liu L, Su H, Liu Y, Liu Y, Xu D.
    Antiviral Res; 2018 Jun; 154():26-34. PubMed ID: 29630974
    [Abstract] [Full Text] [Related]

  • 5. Possible Involvement of Multidrug-Resistant Hepatitis B Virus sW172* Truncation Variant in the ER Stress Signaling Pathway during Hepatocarcinogenesis.
    Zheng J, Jiang S, Lu F.
    Jpn J Infect Dis; 2016 Jul 22; 69(4):306-13. PubMed ID: 26567840
    [Abstract] [Full Text] [Related]

  • 6. The oncogenic potential of hepatitis B virus rtA181T/ surface truncation mutant.
    Lai MW, Yeh CT.
    Antivir Ther; 2008 Jul 22; 13(7):875-9. PubMed ID: 19043921
    [Abstract] [Full Text] [Related]

  • 7. Complementation of Wild-Type and Drug-Resistant Hepatitis B Virus Genomes to Maintain Viral Replication and Rescue Virion Production under Nucleos(t)ide Analogs.
    Wu C, Li B, Zhang X, Zhao K, Chen Y, Yuan Y, Liu Y, Chen R, Xu D, Chen X, Lu M.
    Virol Sin; 2019 Aug 22; 34(4):377-385. PubMed ID: 31218588
    [Abstract] [Full Text] [Related]

  • 8. Development of HBV S gene mutants in chronic hepatitis B patients receiving nucleotide/nucleoside analogue therapy.
    Yeh CT.
    Antivir Ther; 2010 Aug 22; 15(3 Pt B):471-5. PubMed ID: 20516567
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Clinical emergence features and implications of hepatitis B virus rtA181T mutation].
    Li X, Jiang L, Li F, Liu Y, Dai J, Zhao P, Qin Y, Li J, Xu D.
    Zhonghua Gan Zang Bing Za Zhi; 2015 Jan 22; 23(1):23-7. PubMed ID: 25751382
    [Abstract] [Full Text] [Related]

  • 11. Supportive role played by precore and preS2 genomic changes in the establishment of lamivudine-resistant hepatitis B virus.
    Ohkawa K, Takehara T, Kato M, Deguchi M, Kagita M, Hikita H, Sasakawa A, Kohga K, Uemura A, Sakamori R, Yamaguchi S, Miyagi T, Ishida H, Tatsumi T, Hayashi N.
    J Infect Dis; 2008 Oct 15; 198(8):1150-8. PubMed ID: 18713056
    [Abstract] [Full Text] [Related]

  • 12. Biological characteristics comparison of HBV rtA181T mutants with truncated or substituted HBsAg expression in vitro and in vivo model systems.
    Zhou LY, Chen EQ, Wang ML, Chen LL, Liu CP, Zeng F, Tang H.
    Sci Rep; 2016 Dec 15; 6():39260. PubMed ID: 27976732
    [Abstract] [Full Text] [Related]

  • 13. In vitro characterization of viral fitness of therapy-resistant hepatitis B variants.
    Villet S, Billioud G, Pichoud C, Lucifora J, Hantz O, Sureau C, Dény P, Zoulim F.
    Gastroenterology; 2009 Jan 15; 136(1):168-176.e2. PubMed ID: 18996386
    [Abstract] [Full Text] [Related]

  • 14. Hepatitis B virus mutations associated with antiviral therapy.
    Bartholomeusz A, Locarnini S.
    J Med Virol; 2006 Jan 15; 78 Suppl 1():S52-5. PubMed ID: 16622878
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Nucleos(t)ide analogues causes HBV S gene mutations and carcinogenesis.
    Wang ML, Tang H.
    Hepatobiliary Pancreat Dis Int; 2016 Dec 15; 15(6):579-586. PubMed ID: 27919846
    [Abstract] [Full Text] [Related]

  • 17. Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutants.
    Tacke F, Gehrke C, Luedde T, Heim A, Manns MP, Trautwein C.
    J Virol; 2004 Aug 15; 78(16):8524-35. PubMed ID: 15280461
    [Abstract] [Full Text] [Related]

  • 18. Biological characteristics of the rtA181T/sW172* mutant strain of Hepatitis B virus in animal model.
    Dai J, Chen EQ, Bai L, Gong DY, Zhou QL, Cheng X, Huang FJ, Tang H.
    Virol J; 2012 Nov 21; 9():280. PubMed ID: 23171829
    [Abstract] [Full Text] [Related]

  • 19. In vitro resistance to interferon-alpha of hepatitis B virus with basic core promoter double mutation.
    Wang Y, Wei L, Jiang D, Cong X, Fei R, Chen H, Xiao J, Wang Y.
    Antiviral Res; 2007 Aug 21; 75(2):139-45. PubMed ID: 17397939
    [Abstract] [Full Text] [Related]

  • 20. A dominant hepatitis B virus population defective in virus secretion because of several S-gene mutations from a patient with fulminant hepatitis.
    Kalinina T, Riu A, Fischer L, Will H, Sterneck M.
    Hepatology; 2001 Aug 21; 34(2):385-94. PubMed ID: 11481624
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.